Researchers at Kanazawa University, in collaboration with a scientist at Roswell Park Comprehensive Cancer Center, report that adding a brief course of a SUMOylation inhibitor to CD19 CAR-T therapy produced long-term cures in 80% of mice bearing a high burden of Burkitt's lymphoma.
Burkitt's lymphoma is
